Search Results - "Bengtson, Elizabeth M."

Consolidation Therapy With Subcutaneous Alemtuzumab After Fludarabine and Rituximab Induction Therapy for Previously Untreated Chronic Lymphocytic Leukemia: Final Analysis of CALGB 10101 by LIN, Thomas S, DONOHUE, Kathleen A, BYRD, John C, LUCAS, Margaret S, HOKE, Eva E, BENGTSON, Elizabeth M, RAI, Kanti R, ATKINS, James N, LINK, Brian K, LARSON, Richard A

“…To determine if alemtuzumab consolidation improves response rate and progression-free survival (PFS) after induction chemoimmunotherapy in previously untreated…”
Get full text

Methotrexate encephalopathy: Two cases in adult cancer patients, who recovered with pathophysiologically based therapy by Coker, Shodeinde A, Pastel, David A, Davis, Melissa C, Bengtson, Elizabeth M, Fadul, Camilo E, Lewis, Lionel D

“…Background/Objectives: Neurotoxicity is a serious and sometimes fatal adverse effect that can occur following methotrexate treatment. We describe two adult…”
Get full text

Cytogenetically cryptic insertion of PML segment into RARA on chromosome 17q resulting PML-RARA fusion in acute promyelocytic leukemia by Burns, Timothy F., Loo, Eric Y., Bengtson, Elizabeth M., Bao, Liming

Get full text

Randomized phase 3 study in low‐grade lymphoma comparing maintenance anti‐CD20 antibody with observation after induction therapy: A trial of the ECOG‐ACRIN Cancer Research Group (E1496) by Barta, Stefan K., Li, Hailun, Hochster, Howard S., Hong, Fangxin, Weller, Edie, Gascoyne, Randy D., Habermann, Thomas M., Gordon, Leo I., Colocci, Natalia, Bengtson, Elizabeth M., Horning, Sandra J., Kahl, Brad S.

“…BACKGROUND In an ECOG‐ACRIN Cancer Research Group study (E1496), maintenance rituximab (MR) was reported to prolong progression‐free survival (PFS) in…”
Get full text

Profound autoimmune hemolysis and Evans syndrome in two asplenic patients with babesiosis by Shatzel, Joseph J., Donohoe, Kelsey, Chu, Ngoc‐Quynh, Garratty, George, Mody, Kabir, Bengtson, Elizabeth M., Dunbar, Nancy M.

“…Background Evans syndrome (ES) is characterized by the simultaneous or sequential presence of multiple autoimmune cytopenias. It is often secondary to…”
Get full text

Preclinical Medical Student Hematology/Oncology Education Environment by Zumberg, Marc S., Broudy, Virginia C., Bengtson, Elizabeth M., Gitlin, Scott D.

“…To better prepare medical students to care for patients in today’s changing health-care environment as they transition to continuing their education as…”
Get full text

A Randomized Phase III Study in Low Grade Lymphoma Comparing Maintenance Anti-CD20 Antibody versus Observation following Induction Therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496) by Barta, Stefan K., Li, Hailun, Hochster, Howard S., Hong, Fangxin, Weller, Edie, Gascoyne, Randy D., Habermann, Thomas M., Gordon, Leo I., Colocci, Natalia, Bengtson, Elizabeth M, Horning, Sandra J., Kahl, Brad S.

Get full text

Profound autoimmune hemolysis and E vans syndrome in two asplenic patients with babesiosis by Shatzel, Joseph J., Donohoe, Kelsey, Chu, Ngoc‐Quynh, Garratty, George, Mody, Kabir, Bengtson, Elizabeth M., Dunbar, Nancy M.

“…Background E vans syndrome ( ES ) is characterized by the simultaneous or sequential presence of multiple autoimmune cytopenias. It is often secondary to…”
Get full text

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab After Fludarabine and Rituximab (FR) Induction Therapy Improves the Complete Response (CR) Rate in Chronic Lymphocytic Leukemia (CLL) and Eradicates Minimal Residual Disease (MRD) but Is Associated with Severe Infectious Toxicity: Final Analysis of CALGB Study 10101 by Lin, Thomas S, Donohue, Kathleen A, Byrd, John C., Lucas, Margaret S, Hoke, Eva, Bengtson, Elizabeth M, Atkins, James N, Link, Brian K, Rai, Kanti R, Larson, Richard A

“…Abstract 210 Alemtuzumab (Campath-1H) is approved for the treatment of CLL. CALGB sought to determine whether alemtuzumab can improve the CR rate and eradicate…”
Get full text

Consolidation Therapy with Subcutaneous (SC) Alemtuzumab Results in Severe Infectious Toxicity in Previously Untreated CLL Patients Who Achieve a Complete Response (CR) after Fludarabine and Rituximab (FR) Induction Therapy: Interim Safety Analysis of the CALGB Study 10101 by Lin, Thomas S., Donohue, Kathleen A., Lucas, Margaret S., Byrd, John C., Bengtson, Elizabeth M., Peterson, Bercedis L., Larson, Richard A.

“…Alemtuzumab (Campath-1H) is approved for the treatment of fludarabine-refractory chronic lymphocytic leukemia (CLL). Given the increasing role of…”
Get full text

Pilot Study of Low Dose Melphalan and Bortezomib for Treatment of Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndromes by Bubis, Jeffrey A., Ely, Pamela, Meehan, Kenneth R., Stearns, Diane, Schaal, Anna D., Kimtis, Elizabeth A., Lowrey, Christopher, Bengtson, Elizabeth M., Hill, John, Gautier, Marc

“…Elderly patients with AML (>60) have a poor prognosis due to high risk cytogenetics and a high incidence of secondary AML. Comorbid conditions make induction…”
Get full text

Successful PBSC Mobilization, Collection, Transplantation and Engraftment after Radioimmunotherapy with Yttrium-90 Ibritumomab Tiuxetan for Non-Hodgkin's Lymphoma (NHL) by Ely, Pamela, Stearns, Diane M., Zaki, Bassem I., Fitzmaurice, Thomas F., Gautier, Marc, Lowrey, Christopher H., Bengtson, Elizabeth M., Hill, John M., Schaal, Anna D., Kimtis, Elizabeth A., Root, Lynn, Webber, Susan, Szczepiorkowski, Zbigniew M., Meehan, Kenneth R.

“…Radioimmunotherapy (RIT) is a useful addition to the armamentarium against NHL. Due to concerns about chronic myelosuppression and the possible inability to…”
Get full text

New oral chemotherapeutic agents for lung cancer by BENGTSON, E. M, RIGAS, J. R

“…Anticancer treatment has recently shifted to include a broad range of antineoplastic therapies. Old agents are continuously being re-evaluated, and new…”
Get full text

Cytogenetically cryptic insertion of PML segment into RARA on chromosome 17q resulting PML-RARA fusion in acute promyelocytic leukemia by Burns, Timothy F, Loo, Eric Y, Bengtson, Elizabeth M, Bao, Liming

Get full text

Methotrexate encephalopathy: Two cases in adult cancer patients, who recovered with pathophysiologically based therapy by Coker, Shodeinde A, Pastel, David A, Davis, Melissa C, Bengtson, Elizabeth M, Fadul, Camilo E, Lewis, Lionel D

“…BACKGROUND/OBJECTIVESNeurotoxicity is a serious and sometimes fatal adverse effect that can occur following methotrexate treatment. We describe two adult…”
Get full text

Profound autoimmune hemolysis and Evans syndrome in two asplenic patients with babesiosis by Shatzel, Joseph J., Donohoe, Kelsey, Chu, Ngoc-Quynh, Garratty, George, Mody, Kabir, Bengtson, Elizabeth M., Dunbar, Nancy M.

Get full text